Aug 13, 2026 04:00PM

Jul 28, 2026 06:00AM

Jul 28, 2026 06:00AM

Jul 27, 2026 04:00PM

Jul 27, 2026 04:00PM

Jul 14, 2026 05:50AM

Jul 14, 2026 02:30AM ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

May 12, 2026 06:30AM

Apr 13, 2026 07:30AM

Mar 25, 2026 08:00AM

Mar 18, 2026 08:00AM

Mar 18, 2026 08:00AM

Feb 4, 2026 04:05PM

Dec 18, 2025 07:30AM ProMIS Neurosciences completes enrollment in alzheimer's drug trial

Dec 18, 2025 07:30AM

Dec 10, 2025 07:30AM

Dec 10, 2025 07:30AM

Dec 1, 2025 07:30AM

Dec 1, 2025 07:30AM

Dec 1, 2025 07:00AM

Nov 12, 2025 07:00AM ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Nov 12, 2025 07:00AM

Nov 3, 2025 04:05PM

Oct 22, 2025 07:31AM

Oct 22, 2025 07:30AM

Sep 3, 2025 07:00AM

Sep 3, 2025 07:00AM

Aug 13, 2025 07:00AM ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

Aug 13, 2025 07:00AM

Jul 29, 2025 08:00AM

Jul 29, 2025 08:00AM

Jul 22, 2025 06:40AM

Jul 21, 2025 08:04AM

Jul 21, 2025 08:00AM

Nov 14, 2023 04:30PM ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Aug 14, 2023 05:33PM

Jul 17, 2023 07:00AM

May 15, 2023 05:00PM

May 8, 2023 09:00AM

May 8, 2023 09:00AM

Apr 10, 2023 07:30AM

Apr 10, 2023 07:30AM ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

Apr 10, 2023 07:30AM

Mar 29, 2023 08:31AM

Mar 29, 2023 08:30AM

Mar 29, 2023 08:30AM

Mar 8, 2023 05:06PM

Mar 8, 2023 05:06PM

Nov 14, 2022 07:00AM ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights

Nov 14, 2022 07:00AM

329,957 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All